

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
11 May 2023 (11.05.2023)



(10) International Publication Number
WO 2023/081923 A1

(51) International Patent Classification:

C07D 487/04 (2006.01) A61P 25/28 (2006.01)
C07D 471/04 (2006.01) A61P 27/00 (2006.01)
A61P 25/00 (2006.01) A61K 31/437 (2006.01)

(21) International Application Number:

PCT/US2022/079480

(22) International Filing Date:

08 November 2022 (08.11.2022)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/277,145 08 November 2021 (08.11.2021) US
63/378,431 05 October 2022 (05.10.2022) US

(71) Applicant: **FREQUENCY THERAPEUTICS, INC.**
[US/US]; 75 Hayden Avenue, Suite 300, Lexington, Massachusetts 02421 (US).

(72) Inventors: **MAGAVI, Sanjay Shivayogi**; c/o Frequency Therapeutics, Inc., 75 Hayden Avenue, Suite 300, Lexington, Massachusetts 02421 (US). **PARKS, Daniel J.**; c/o Frequency Therapeutics, Inc., 75 Hayden Avenue, Suite 300, Lexington, Massachusetts 02421 (US). **TAIT, Bradley Dean**; c/o Frequency Therapeutics, Inc., 75 Hayden Avenue, Suite 300, Lexington, Massachusetts 02421 (US). **CHO, Jinhyung**; c/o Frequency Therapeutics, Inc., 75 Hayden Avenue, Suite 300, Lexington, Massachusetts 02421 (US). **AGRAWAL, Rajiv**; c/o Frequency Therapeutics, Inc., 75 Hayden Avenue, Suite 300, Lexington, Massachusetts 02421 (US). **SHAW, Patricia R.**; c/o Frequency Therapeutics, Inc., 75 Hayden Avenue, Suite 300, Lexington, Massachusetts 02421 (US).

(74) Agent: **FRUEAUF, Jeremiah B.** et al.; STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C., 1100 New York Avenue, NW, Washington, District of Columbia 20005 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- of inventorship (Rule 4.17(iv))

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))
- with sequence listing part of description (Rule 5.2(a))

(54) Title: PLATELET-DERIVED GROWTH FACTOR RECEPTOR (PDGFR) ALPHA INHIBITORS AND USES THEREOF

(57) Abstract: The present disclosure provides compounds that can specifically target a PDGFR α , and thereby, reduce and/or inhibit the activation of the receptor ("PDGFR α inhibitor"). The present disclosure also provides methods of treating a demyelinating disease using the disclosed PDGFR α inhibitors.

WO 2023/081923 A1